Abb Vie Deutschland Gmbh & Co. Kg

Abbvie Deutschland Gmbh and Co Kg

Carsten Krantz

Heinz Hillen

Achim Moeller

Andreas R Striebinger

Reinhold Mueller

Ulrich Ebert

Stefan Barghorn

Volker Nimmrich

Gerhard Gross

Andreas Draguhn

Claus Bruhl

Christine Grimm

The invention relates to neuromodulatory oligomers of the amyloid-&#x3b2;(1-42) protein, a particular production method, by means of which the oligomer can be obtained in a reproducible manner at high yield, the use of the oligomers as diagnostic and therapeutics agents, for the generation of oligomer-specific antibodies and for the discovery of substances which can interact with the oligomers and in the formation thereof. Corresponding methods for the production of the antibodies and for discovery of the substances are also disclosed as are the antibodies themselves and the use of the antibodies or substances as diagnostic and therapeutic agents. The invention further relates to derivatives of the oligomers and oligomers based on abbreviated forms of the amyloid-&#x3b2;(1-42) proteins, the production and use thereof.

Amyloid &#x3b2;(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof

Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof

The present invention relates to a method for the treatment of an amyloidosis such as Alzheimer's disease in a subject in need thereof, characterized in that it comprises administering an inhibitor of the interaction between A&#x3b2; globulomer and the P/Q type voltage-gated presynaptic calcium channel to said subject.

Method for the treatment of amyloidoses

Growing community of inventors

Mannheim, Germany

Carsten Krantz